These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16113946)

  • 1. Antifungal agents.
    Ryder NS
    IDrugs; 1999 Dec; 2(12):1253-5. PubMed ID: 16113946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal drug discovery and development--fourth international summit. 10-11 March 1999, Princeton, New Jersey, USA.
    Ryder N
    IDrugs; 1999 May; 2(5):410-3. PubMed ID: 16155842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in antifungal chemotherapy.
    Fromtling RA
    Drug News Perspect; 1998 Nov; 11(9):582-95. PubMed ID: 15616671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal agents: mode of action in yeast cells.
    Carrillo-Muñoz AJ; Giusiano G; Ezkurra PA; Quindós G
    Rev Esp Quimioter; 2006 Jun; 19(2):130-9. PubMed ID: 16964330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for the treatment of systemic fungal infections--current status.
    Arikan S; Rex JH
    Expert Opin Emerg Drugs; 2002 May; 7(1):3-32. PubMed ID: 15989533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
    Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
    J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical microbiology and infectious diseases. Management of fungal infections.
    Arikan S
    IDrugs; 2001 Jul; 4(7):746-9. PubMed ID: 15995924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
    Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
    J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH; Guglielmo BJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
    Martino R; Viscoli C
    Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging treatments for fungal infections.
    Pasqualotto AC; Denning DW
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i19-30. PubMed ID: 18063600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Echinocandins in invasive candidiasis].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.